Search Results

“You don’t spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings.

Deciphering the tumor microenvironment using patient-derived scaffolds and single-cell triomics Anders Ståhlberg, Professor of Clinical Genomics at the University of Gothenburg, presents patient-derived scaffolds: decellularized tumor tissue that keeps the 3D structure and protein makeup of the original tumor. He shows how his group uses these scaffolds to find prognostic biomarkers in colorectal cancer and to test treatment response in conditions close to in vivo. He also covers single-cell triomics on the Tapestri® platform, which profiles SNVs, CNVs, RNA, and protein from the same cell to show tumor heterogeneity.

Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s ‘disease agnostic’ pipeline and approach to business development.

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.